LEADER
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
Patient / Population Intervention / Exposure Comparison Outcome
In 9,340 patients with type 2 diabetes at high cardiovascular risk, liraglutide reduced major adverse cardiovascular events compared with placebo.
N
9,340
Design
Double-blind RCT
Endpoint
CV death, MI or stroke
Relevance
2
Result13.0 % vs 14.9 % (HR 0.87); CV and all-cause mortality reduced.
Marso SP, et al. N Engl J Med. 2016;375(4):311-322. 10.1056/NEJMoa1603827
Discussion & critique
Established the cardiovascular benefit of GLP-1 receptor agonists — roughly a 14 % MACE reduction is now regarded as a class effect.